FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313308264> ?p ?o ?g. }

• W2313308264 endingPage "S1" @default.
• W2313308264 startingPage "S1" @default.
• W2313308264 abstract "Interleukins 12&23 are implicated in the pathophysiology of Crohn's disease (CD). These pro-inflammatory cytokines are blocked by ustekinumab (UST). In a previous Phase 2b study (CERTIFI),1 UST IV induction followed by SC maintenance was shown effective in moderate-severe CD refractory to anti-TNF therapy. This Phase 3 study examined the efficacy and safety of IV UST induction in these patients. Patients with moderate-severely active CD (CDAI 220–450) who previously failed or were intolerant to at least 1 TNF-antagonist were randomized (1:1:1) at Week (Wk) 0 to a single dose of IV placebo (PBO), UST 130 mg, or weight-based tiered UST dosing approximating 6 mg/kg (260mg [weight ≤55 kg], 390mg [weight >55 kg and ≤85 kg], 520mg [weight >85 kg]). The primary endpoint was clinical response at Wk6, defined as reduction from baseline in the CDAI score of >100 points; patients with baseline CDAI score >220 to <248 points were considered in clinical response if a CDAI score of <150 was present. At Wk8, patients either transitioned to the IM-UNITI maintenance study or were followed to Wk20. The 741 randomized patients had a history of TNF-antagonist failure, with baseline median CDAI of 317, CRP of 9.9 mg/L, and prior disease duration of 10.1 years. Of these, 51% had previously failed ≥2 anti-TNFs with 29.1%, 69.4%, and 36.4% of patients, respectively, satisfying protocol criteria for primary non-response, secondary non-response, or intolerance to at least one TNF antagonist. Statistical significance was demonstrated for the primary and all 4 major secondary endpoints at both IV doses. Clinical response at Wk6 (primary endpoint) was observed in 33.7% of the ∼6 mg/kg and 34.3% of the 130 mg UST groups versus 21.5% in PBO (P = 0.003 and 0.002, respectively). Clinical remission (CDAI <150) at Wk8 was observed in 20.9% of the ∼6 mg/kg group and 15.9% of the 130 mg UST group versus 7.3% on PBO (P < 0.001, P = 0.003, respectively). Clinical response at Wk8 was seen in 37.8% of the ∼6 mg/kg and 33.5% of the 130 mg UST groups, versus 20.2% on PBO (each P ≤ 0.001). Proportion of patients with 70pt CDAI response at Wk6 was 43.8% of the ∼6 mg/kg and 46.1% of the 130 mg UST groups versus 30.4% in PBO (P = 0.002 and <0.001, respectively) and at the first post-baseline Wk3 visit, 40.6% in ∼6 mg/kg and 38.4% in the 130 mg UST groups versus 27.1% in PBO (P = 0.001 and P = 0.009, respectively), the final major secondary endpoint. Both IV UST induction doses additionally resulted in significant improvements in CDAI, IBDQ, CRP, fecal lactoferrin and calprotectin versus IV PBO. Proportions of patients with AEs, SAEs, and infections were similar in the UST and PBO groups. One opportunistic infection (listeria meningitis) was reported in the ∼6 mg/kg UST group. No malignancies, deaths, major adverse cardiovascular events, or TB occurred in UST-treated patients through Wk20. In a population of moderate-severe CD patients refractory to one or more prior TNF-antagonists, IV UST induced clinical response and remission and was well-tolerated throughout induction, confirming the previous positive induction data from the Phase 2b CERTIFI study." @default.
• W2313308264 created "2016-06-24" @default.
• W2313308264 creator A5009242946 @default.
• W2313308264 creator A5011739304 @default.
• W2313308264 creator A5015470174 @default.
• W2313308264 creator A5017140014 @default.
• W2313308264 creator A5019474609 @default.
• W2313308264 creator A5026638199 @default.
• W2313308264 creator A5032150391 @default.
• W2313308264 creator A5045988031 @default.
• W2313308264 creator A5046814722 @default.
• W2313308264 creator A5048464948 @default.
• W2313308264 creator A5048480454 @default.
• W2313308264 creator A5051870878 @default.
• W2313308264 creator A5052113690 @default.
• W2313308264 creator A5052878644 @default.
• W2313308264 creator A5068927209 @default.
• W2313308264 creator A5072959244 @default.
• W2313308264 creator A5073322732 @default.
• W2313308264 creator A5087140986 @default.
• W2313308264 date "2016-03-01" @default.
• W2313308264 modified "2023-10-16" @default.
• W2313308264 title "O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα" @default.
• W2313308264 cites W2085127303 @default.
• W2313308264 doi "https://doi.org/10.1097/mib.0000000000000720" @default.
• W2313308264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26849718" @default.
• W2313308264 hasPublicationYear "2016" @default.
• W2313308264 type Work @default.
• W2313308264 sameAs 2313308264 @default.
• W2313308264 citedByCount "41" @default.
• W2313308264 countsByYear W23133082642016 @default.
• W2313308264 countsByYear W23133082642017 @default.
• W2313308264 countsByYear W23133082642018 @default.
• W2313308264 countsByYear W23133082642019 @default.
• W2313308264 countsByYear W23133082642020 @default.
• W2313308264 countsByYear W23133082642021 @default.
• W2313308264 crossrefType "journal-article" @default.
• W2313308264 hasAuthorship W2313308264A5009242946 @default.
• W2313308264 hasAuthorship W2313308264A5011739304 @default.
• W2313308264 hasAuthorship W2313308264A5015470174 @default.
• W2313308264 hasAuthorship W2313308264A5017140014 @default.
• W2313308264 hasAuthorship W2313308264A5019474609 @default.
• W2313308264 hasAuthorship W2313308264A5026638199 @default.
• W2313308264 hasAuthorship W2313308264A5032150391 @default.
• W2313308264 hasAuthorship W2313308264A5045988031 @default.
• W2313308264 hasAuthorship W2313308264A5046814722 @default.
• W2313308264 hasAuthorship W2313308264A5048464948 @default.
• W2313308264 hasAuthorship W2313308264A5048480454 @default.
• W2313308264 hasAuthorship W2313308264A5051870878 @default.
• W2313308264 hasAuthorship W2313308264A5052113690 @default.
• W2313308264 hasAuthorship W2313308264A5052878644 @default.
• W2313308264 hasAuthorship W2313308264A5068927209 @default.
• W2313308264 hasAuthorship W2313308264A5072959244 @default.
• W2313308264 hasAuthorship W2313308264A5073322732 @default.
• W2313308264 hasAuthorship W2313308264A5087140986 @default.
• W2313308264 hasBestOaLocation W23133082641 @default.
• W2313308264 hasConcept C121332964 @default.
• W2313308264 hasConcept C126322002 @default.
• W2313308264 hasConcept C142424586 @default.
• W2313308264 hasConcept C142724271 @default.
• W2313308264 hasConcept C168563851 @default.
• W2313308264 hasConcept C170493617 @default.
• W2313308264 hasConcept C17991360 @default.
• W2313308264 hasConcept C197934379 @default.
• W2313308264 hasConcept C202953159 @default.
• W2313308264 hasConcept C203092338 @default.
• W2313308264 hasConcept C204243189 @default.
• W2313308264 hasConcept C204787440 @default.
• W2313308264 hasConcept C27081682 @default.
• W2313308264 hasConcept C2776260265 @default.
• W2313308264 hasConcept C2776885963 @default.
• W2313308264 hasConcept C2777138892 @default.
• W2313308264 hasConcept C2777288759 @default.
• W2313308264 hasConcept C2778975655 @default.
• W2313308264 hasConcept C2779134260 @default.
• W2313308264 hasConcept C2779280984 @default.
• W2313308264 hasConcept C2779745271 @default.
• W2313308264 hasConcept C2779786854 @default.
• W2313308264 hasConcept C71924100 @default.
• W2313308264 hasConcept C87355193 @default.
• W2313308264 hasConcept C90924648 @default.
• W2313308264 hasConceptScore W2313308264C121332964 @default.
• W2313308264 hasConceptScore W2313308264C126322002 @default.
• W2313308264 hasConceptScore W2313308264C142424586 @default.
• W2313308264 hasConceptScore W2313308264C142724271 @default.
• W2313308264 hasConceptScore W2313308264C168563851 @default.
• W2313308264 hasConceptScore W2313308264C170493617 @default.
• W2313308264 hasConceptScore W2313308264C17991360 @default.
• W2313308264 hasConceptScore W2313308264C197934379 @default.
• W2313308264 hasConceptScore W2313308264C202953159 @default.
• W2313308264 hasConceptScore W2313308264C203092338 @default.
• W2313308264 hasConceptScore W2313308264C204243189 @default.
• W2313308264 hasConceptScore W2313308264C204787440 @default.
• W2313308264 hasConceptScore W2313308264C27081682 @default.
• W2313308264 hasConceptScore W2313308264C2776260265 @default.
• W2313308264 hasConceptScore W2313308264C2776885963 @default.
• W2313308264 hasConceptScore W2313308264C2777138892 @default.
• W2313308264 hasConceptScore W2313308264C2777288759 @default.

• next